As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.

May 10, 2024

Vol.50 No.19

By Sanju Sinha and Eytan Ruppin

Guest Editorial

OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like?

May 10, 2024

Vol.50 No.19

By Steven C. Cunningham, Donna R. Rivera, Richard Pazdur, Kelly J. Norsworthy and Jennifer Gao

Clinical Roundup

AI-based biomarker stratifies metastasis risk in patients with BCR post-prostatectomy

ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.

May 10, 2024

Vol.50 No.19

Clinical Roundup

AI tool predicts success of focal therapy for prostate cancer

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveiled the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments.

May 10, 2024

Vol.50 No.19

Drugs & Targets

FDA accepts BLA for subcutaneous Opdivo

FDA has accepted the Bristol Myers Squibb’s Biologics License Application for the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20)—herein referred to as “subcutaneous nivolumab”—across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.

May 10, 2024

Vol.50 No.19

Health Equity White House

Citing need for “more conversations” on menthol, White House scuttles move to ban the flavor favored by Black smokers

The Biden administration has—for the second time—delayed the decision on a proposed FDA rule that would ban menthol cigarettes and all flavors in cigars.

May 03, 2024

Vol.50 No.18

By McKenzie Prillaman

As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change

YOU MAY BE INTERESTED IN

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

AI-based biomarker stratifies metastasis risk in patients with BCR post-prostatectomy

AI tool predicts success of focal therapy for prostate cancer

FDA accepts BLA for subcutaneous Opdivo

Citing need for “more conversations” on menthol, White House scuttles move to ban the flavor favored by Black smokers

Renew today!

Subscriber content

Login